{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:00:51Z","timestamp":1785438051860,"version":"3.56.0"},"reference-count":52,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"\u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy Cluj-Napoca"},{"id":[{"id":"https:\/\/ror.org\/051h0cw83","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>In patients with advanced or metastatic melanoma, BRAF mutation assessment is routinely performed to identify patients who may benefit from BRAF-targeted therapy. This study aimed to assess the role of BRAF mutation status in relation to histopathological characteristics and survival of patients with stage II and III malignant melanoma. A prospective cohort of 108 patients with pT3 malignant melanoma who were treated in a comprehensive cancer center were included in the analysis. All patients were treated according to contemporary melanoma management guidelines between 2016 and 2024, with a minimum follow-up of 12 months extending to 2025. Overall survival (OS) and progression-free survival (PFS) analyses were performed in the study cohort. The study included 108 patients with stage II\u2013III malignant melanoma, with a mean age of 56.73 \u00b1 13.51 years. Superficial spreading melanoma was the most frequent histological subtype, followed by nodular and acral melanoma. Most tumors were classified as Clark level IV, with a median Breslow thickness of 3 mm, and ulceration was present in the majority of cases. Lymph node involvement was observed in over half of the patients, and BRAF mutations were identified in 56.48% of cases (the most common variant was V600E). Brisk tumor-infiltrating lymphocytes were significantly more frequent in BRAF wild-type tumors compared with BRAF-mutant tumors. When assessing associations with survival, BRAF mutation status was not found to be an independent predictor. In the multivariate Cox model, TIL status was associated with improved OS (HR 3.33, 95% CI 1.41\u20137.88, p = 0.006). In addition, in the multivariate analysis, TIL status was also associated with improved PFS (HR 5.23, 95% CI 2.22\u201312.3, p &lt; 0.001). BRAF wild-type tumors were significantly more likely to exhibit a brisk infiltrate. BRAF mutation status was not found to be an independent predictor of survival. TIL status remained significantly associated with OS and PFS in multivariable analysis.<\/jats:p>","DOI":"10.3390\/ijms27146150","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T16:16:44Z","timestamp":1783613804000},"page":"6150","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of BRAF Mutation Status with Histopathological Characteristics and Survival Outcomes in Stage II\u2013III Malignant Melanoma"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-6877","authenticated-orcid":false,"given":"Vlad Alexandru","family":"G\u00e2ta","sequence":"first","affiliation":[{"name":"Department of Oncological Surgery and Gynecological Oncology, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"},{"name":"Department of Surgical Oncology, \u201cProf. Dr. Ion Chiricu\u021b\u0103\u201d Institute of Oncology, 400015 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4218-8622","authenticated-orcid":false,"given":"Daniel Corneliu","family":"Leucu\u021ba","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics and Biostatistics, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radu Alexandru","family":"Ilie\u0219","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5910-8137","authenticated-orcid":false,"given":"\u0218tefan","family":"\u021a\u00ee\u021bu","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, \u201cProf. Dr. Ion Chiricu\u021b\u0103\u201d Institute of Oncology, 400015 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1876-4502","authenticated-orcid":false,"given":"Ana Maria","family":"Mure\u0219an-B\u0103descu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Nicoar\u0103","sequence":"additional","affiliation":[{"name":"Department of Quality Management, \u201cProf. Dr. Ion Chiricu\u021b\u0103\u201d Institute of Oncology, 400015 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7079-1106","authenticated-orcid":false,"given":"Ioan Constantin","family":"Pop","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, \u201cProf. Dr. Ion Chiricu\u021b\u0103\u201d Institute of Oncology, 400015 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5911-983X","authenticated-orcid":false,"given":"Alex Victor","family":"Or\u0103dan","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, \u201cProf. Dr. Ion Chiricu\u021b\u0103\u201d Institute of Oncology, 400015 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian Vlad","family":"Muntean","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, \u201cProf. Dr. Ion Chiricu\u021b\u0103\u201d Institute of Oncology, 400015 Cluj-Napoca, Romania"},{"name":"Department of Plastic and Reconstructive Surgery, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1089-8251","authenticated-orcid":false,"given":"Anda","family":"G\u00e2ta","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ypmed.2016.08.032","article-title":"Melanoma burden and recent trends among non-Hispanic whites aged 15\u201349, United States","volume":"91","author":"Watson","year":"2016","journal-title":"Prev. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/jdv.15322","article-title":"Time trends in incidence and mortality of cutaneous melanoma in Germany","volume":"33","author":"Garbe","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_4","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","unstructured":"National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Programme (2026, March 12). Cancer Stat Facts: Melanoma of the Skin 2020, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/melan.html."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1200\/OP.21.00686","article-title":"Managing Metastatic Melanoma in 2022: A Clinical Review","volume":"18","author":"Switzer","year":"2022","journal-title":"JCO Oncol. Pract."},{"key":"ref_8","first-page":"1287","article-title":"Effectiveness and safety profile of ipilimumab therapy in previously treated patients with unresectable or metastatic melanoma\u2014The Romanian Patient Access Program","volume":"22","author":"Ciuleanu","year":"2017","journal-title":"J. BUON"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/jid.2008.423","article-title":"The increasing burden of melanoma in the United States","volume":"129","author":"Linos","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"a015388","DOI":"10.1101\/cshperspect.a015388","article-title":"Melanoma: Clinical features and genomic insights","volume":"4","author":"Hawryluk","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_11","first-page":"1396","article-title":"Trends in incidence and survival in patients with melanoma, 1974\u20132013","volume":"9","author":"Che","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"ref_12","first-page":"472","article-title":"Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1586\/14737159.2014.928206","article-title":"Immune cells in the melanoma microenvironment hold information for prediction of the risk of recurrence and response to treatment","volume":"14","author":"Camisaschi","year":"2014","journal-title":"Expert. Rev. Mol. Diagn."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Yang, T.T., Yu, S., Ke, C.K., and Cheng, S.T. (2023). The Genomic Landscape of Melanoma and Its Therapeutic Implications. Genes, 14.","DOI":"10.3390\/genes14051021"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Georgoulias, G., and Zaravinos, A. (2022). Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1006665"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1758835919848872","DOI":"10.1177\/1758835919848872","article-title":"Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?","volume":"11","author":"Incorvaia","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Castellani, G., Buccarelli, M., Arasi, M.B., Rossi, S., Pisanu, M.E., Bellenghi, M., Lintas, C., and Tabolacci, C. (2023). BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers. Cancers, 15.","DOI":"10.3390\/cancers15164026"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Szab\u00f3, I.L., Emri, G., Lad\u00e1nyi, A., and T\u00edm\u00e1r, J. (2025). Clinical Applications of the Molecular Landscape of Melanoma: Integration of Research into Diagnostic and Therapeutic Strategies. Cancers, 17.","DOI":"10.3390\/cancers17091422"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","article-title":"BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma","volume":"30","author":"Colombino","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1002\/cncr.28864","article-title":"The MAPK pathway across different malignancies: A new perspective","volume":"120","author":"Burotto","year":"2014","journal-title":"Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1038\/onc.2012.453","article-title":"NRAS mutant melanoma: Biological behaviour and future strategies for therapeutic management","volume":"32","author":"Fedorenko","year":"2013","journal-title":"Oncogene"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1101\/gad.191999.112","article-title":"Melanoma: From mutations to medicine","volume":"26","author":"Tsao","year":"2012","journal-title":"Genes. Dev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"MMT64","DOI":"10.2217\/mmt-2023-0005","article-title":"Incidence of BRAF mutations in cutaneous melanoma: Histopathological and molecular analysis of a Ukrainian population","volume":"10","author":"Dudin","year":"2023","journal-title":"Melanoma Manag."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"nhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Amaral","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00428-017-2113-3","article-title":"Molecular genetic and immunotherapeutic targets in metastatic melanoma","volume":"471","author":"Melis","year":"2017","journal-title":"Virchows Arch."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1111\/jdv.12910","article-title":"Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma","volume":"29","author":"Pracht","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jaad.2015.02.1113","article-title":"Meta-analysis of BRAF mutations and clinicopathologic characteristics in primary melanoma","volume":"72","author":"Kim","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrclinonc.2011.69","article-title":"BRAF-targeted therapy changes the treatment paradigm in melanoma","volume":"8","author":"Ribas","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/bjc.2016.44","article-title":"BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival","volume":"114","author":"Hugdahl","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/1078-0432.CCR-10-2276","article-title":"Clinical correlates of NRAS and BRAF mutations in primary human melanoma","volume":"17","author":"Ellerhorst","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1245\/s10434-012-2457-5","article-title":"Prognostic value of BRAF(V600) mutations in melanoma patients after resection of metastatic lymph nodes","volume":"19","author":"Moreau","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/bjd.12939","article-title":"Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection","volume":"171","author":"Picard","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"631","DOI":"10.4149\/neo_2018_181006N740","article-title":"Clinical and prognostic significance of BRAF V600E mutation in non-metastatic cutaneous melanoma patients","volume":"66","author":"Tas","year":"2019","journal-title":"Neoplasma"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Meckbach, D., Bauer, J., Pflugfelder, A., Meier, F., Busch, C., Eigentler, T.K., Capper, D., von Deimling, A., Mittelbronn, M., and Perner, S. (2014). Survival according to BRAF-V600 tumor mutations\u2014an analysis of 437 patients with primary melanoma. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0086194"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Heppt, M.V., Siepmann, T., Engel, J., Schubert-Fritschle, G., Eckel, R., Mirlach, L., Kirchner, T., Jung, A., Gesierich, A., and Ruzicka, T. (2017). Prognostic significance of BRAF and NRAS mutations in melanoma: A German study from routine care. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3529-5"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1093\/jnci\/81.24.1893","article-title":"Model predicting survival in stage I melanoma based on tumor progression","volume":"81","author":"Clark","year":"1989","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5","article-title":"Prognostic value of tumour infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma","volume":"77","author":"Clemente","year":"1996","journal-title":"Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ejca.2009.05.034","article-title":"Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: Outcome analysis from a single-institution prospectively collected database","volume":"45","author":"Imberti","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1200\/JCO.2011.37.8539","article-title":"Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma","volume":"30","author":"Azimi","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1200\/JCO.2006.08.9755","article-title":"Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma","volume":"25","author":"Taylor","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/000313481107700219","article-title":"Prognostic significance of tumor infiltrating lymphocytes in melanoma","volume":"77","author":"Burton","year":"2011","journal-title":"Am. Surg."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1200\/JCO.2013.51.3002","article-title":"Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study","volume":"31","author":"Thomas","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jamaoncol.2015.0493","article-title":"Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients with Higher-Risk Primary Melanoma","volume":"1","author":"Thomas","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.cmr.0000232300.22032.86","article-title":"NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: A study based on mutation screening by pyrosequencing","volume":"16","author":"Omholt","year":"2006","journal-title":"Melanoma Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/PAT.0000000000000314","article-title":"FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor","volume":"47","author":"Leslie","year":"2015","journal-title":"Pathology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.humpath.2017.12.022","article-title":"Prognostic role of tumoral PDL1 expression and peritumoral FoxP3+ lymphocytes in vulvar melanomas","volume":"73","author":"Selim","year":"2018","journal-title":"Hum. Pathol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"G\u00e2ta, V.A., Pa\u0219ca, A., Roman, A., Muntean, M.V., Morariu, D.\u0218., Bonci, E.A., Dina, C., and Ungureanu, L. (2024). The Expression of Forkhead Box P3 T Regulatory Lymphocytes as a Prognostic Factor in Malignant Melanomas. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25126377"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/14\/6150\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T09:01:52Z","timestamp":1784278912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/14\/6150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":52,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["ijms27146150"],"URL":"https:\/\/doi.org\/10.3390\/ijms27146150","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]}}}